Who is sponsoring NCT04994704?

NCT04994704 is sponsored by Gangnam Severance Hospital.

What condition does NCT04994704 study?

NCT04994704 studies Patients Undergoing Spine Surgery.

What drugs are being tested in NCT04994704?

Interventions: Propfol group, Remimazolam group.

What is the status of NCT04994704?

NCT04994704 is currently COMPLETED.

Last reviewed 2023-07-20 · How we verify

Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam

NCT04994704 NA COMPLETED

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.

Details

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	COMPLETED
Enrolment	73
Start date	Wed Dec 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Patients Undergoing Spine Surgery

Interventions

Propfol group
Remimazolam group

Countries

South Korea